IL276564A - Adrenomedullin (ADM) for the diagnosis and/or prediction of dementia and an anti-adrenomedullin binder for use in the treatment or prevention of dementia - Google Patents
Adrenomedullin (ADM) for the diagnosis and/or prediction of dementia and an anti-adrenomedullin binder for use in the treatment or prevention of dementiaInfo
- Publication number
- IL276564A IL276564A IL276564A IL27656420A IL276564A IL 276564 A IL276564 A IL 276564A IL 276564 A IL276564 A IL 276564A IL 27656420 A IL27656420 A IL 27656420A IL 276564 A IL276564 A IL 276564A
- Authority
- IL
- Israel
- Prior art keywords
- adrenomedullin
- dementia
- adm
- prediction
- diagnosis
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18155682 | 2018-02-08 | ||
| PCT/EP2019/052982 WO2019154900A1 (en) | 2018-02-08 | 2019-02-07 | Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL276564A true IL276564A (en) | 2020-09-30 |
Family
ID=61188647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL276564A IL276564A (en) | 2018-02-08 | 2020-08-06 | Adrenomedullin (ADM) for the diagnosis and/or prediction of dementia and an anti-adrenomedullin binder for use in the treatment or prevention of dementia |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210302440A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3749959A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021513077A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102717599B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN119770645A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019219071A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020014940A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3090736A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL276564A (cg-RX-API-DMAC7.html) |
| MX (1) | MX421834B (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202006686SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019154900A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4110372A1 (en) * | 2020-02-26 | 2023-01-04 | PAM Theragnostics GmbH | Use of peptidylglycine alpha-amidating monooxygenase (pam) for therapeutic purpose |
| EP3871689A1 (en) * | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| JP2023515981A (ja) | 2020-02-26 | 2023-04-17 | ペーアーエム セラノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ペプチジルグリシンαアミド化モノオキシゲナーゼ(PAM)を決定する方法および診断目的でのその使用 |
| US20210285949A1 (en) | 2020-03-16 | 2021-09-16 | Sphingotec Gmbh | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
| EP4680966A1 (en) | 2023-03-17 | 2026-01-21 | PAM Theragnostics GmbH | Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose |
| WO2025133203A1 (en) | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Compounds and methods for a long-lasting pam |
| WO2025133225A1 (en) | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam) |
| WO2026099249A1 (en) | 2024-11-05 | 2026-05-15 | Pam Theragnostics Gmbh | Modified and unmodified peptidylglycine alpha-amidating monooxygenase (pam) for use in subjects having increased amyloid-beta and/or phospho-tau-protein load and/or neuroinflammation |
| WO2026099243A1 (en) | 2024-11-05 | 2026-05-15 | Pam Theragnostics Gmbh | Modified and unmodified peptidyl-glycine alpha-amidating monooxygenase (pam) for use in the treatment or prevention of cerebral hypoperfusion for the improvement of cerebral blood flow (cbf) |
| WO2026132535A1 (en) | 2024-12-20 | 2026-06-25 | B.R.A.H.M.S Gmbh | Pro-adrenomedullin and fragment(s) thereof for diagnosis and/or prognosis of a central nervous system inflammation |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| CN1628126A (zh) | 2001-08-30 | 2005-06-15 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| AU2005287557B2 (en) | 2004-09-21 | 2011-10-13 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| DE102005036094A1 (de) * | 2005-08-01 | 2007-02-08 | B.R.A.H.M.S Ag | In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen |
| US20090306227A1 (en) | 2005-08-31 | 2009-12-10 | Toshiyuki Ioka | Tablet for removing tongue coating |
| DE102006027818A1 (de) * | 2006-06-16 | 2007-12-20 | B.R.A.H.M.S. Aktiengesellschaft | In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen |
| DE102006060112A1 (de) | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| WO2009095454A2 (de) * | 2008-02-01 | 2009-08-06 | Brahms Aktiengesellschaft | Verfahren zur identifizierung von therapiebedürftigen patienten mit leichten kognitiven störungen und die behandlung derartiger patienten |
| NZ592591A (en) | 2008-11-03 | 2012-04-27 | Molecular Partners Ag | Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction |
| CA2772162C (en) | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
| BR112012014417B1 (pt) | 2009-12-14 | 2021-11-09 | Scil Proteins Gmbh | Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina |
| AU2011263786B2 (en) | 2010-06-08 | 2014-11-13 | Astrazeneca Ab | Tear lipocalin muteins binding IL-4 R alpha |
| FR2964103B1 (fr) * | 2010-08-30 | 2018-11-23 | Universite D'aix-Marseille | Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament |
| BR112014011670B1 (pt) * | 2011-11-16 | 2021-05-25 | Adrenomed Ag | anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou um arcabouço de proteína não-igg anti-adm que se liga à adrenomedulina e formulação farmacêutica |
| US9140696B2 (en) | 2011-11-16 | 2015-09-22 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| US20160230227A1 (en) * | 2012-12-21 | 2016-08-11 | The New York Stem Cell Foundation | Methods of treating alzheimer's disease |
| CN109716136B (zh) * | 2016-07-08 | 2023-09-22 | 斯弗因高泰克有限公司 | 肾上腺髓质素用于评估急性心力衰竭患者的充血 |
-
2019
- 2019-02-07 KR KR1020207025729A patent/KR102717599B1/ko active Active
- 2019-02-07 AU AU2019219071A patent/AU2019219071A1/en not_active Abandoned
- 2019-02-07 JP JP2020542645A patent/JP2021513077A/ja active Pending
- 2019-02-07 US US16/968,483 patent/US20210302440A1/en active Pending
- 2019-02-07 CA CA3090736A patent/CA3090736A1/en active Pending
- 2019-02-07 BR BR112020014940-3A patent/BR112020014940A2/pt not_active IP Right Cessation
- 2019-02-07 CN CN202411684173.XA patent/CN119770645A/zh active Pending
- 2019-02-07 EP EP19702467.2A patent/EP3749959A1/en active Pending
- 2019-02-07 CN CN201980012542.1A patent/CN111902721B/zh active Active
- 2019-02-07 MX MX2020008345A patent/MX421834B/es unknown
- 2019-02-07 SG SG11202006686SA patent/SG11202006686SA/en unknown
- 2019-02-07 WO PCT/EP2019/052982 patent/WO2019154900A1/en not_active Ceased
-
2020
- 2020-08-06 IL IL276564A patent/IL276564A/en unknown
-
2022
- 2022-12-30 US US18/148,633 patent/US20230221339A1/en active Pending
-
2023
- 2023-10-06 JP JP2023174585A patent/JP2024001208A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102717599B1 (ko) | 2024-10-14 |
| CN111902721B (zh) | 2024-12-13 |
| MX421834B (es) | 2025-03-14 |
| CN119770645A (zh) | 2025-04-08 |
| CA3090736A1 (en) | 2019-08-15 |
| KR20200135947A (ko) | 2020-12-04 |
| RU2020129154A (ru) | 2022-03-10 |
| CN111902721A (zh) | 2020-11-06 |
| MX2020008345A (es) | 2020-09-25 |
| JP2024001208A (ja) | 2024-01-09 |
| WO2019154900A1 (en) | 2019-08-15 |
| US20210302440A1 (en) | 2021-09-30 |
| JP2021513077A (ja) | 2021-05-20 |
| BR112020014940A2 (pt) | 2020-12-08 |
| EP3749959A1 (en) | 2020-12-16 |
| RU2020129154A3 (cg-RX-API-DMAC7.html) | 2022-03-10 |
| US20230221339A1 (en) | 2023-07-13 |
| AU2019219071A1 (en) | 2020-07-30 |
| SG11202006686SA (en) | 2020-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202006686SA (en) | Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia | |
| IL279347A (en) | Gremlin-1 antagonist for cancer prevention and treatment | |
| IL261333B (en) | 2idh inhibitors for the treatment of hematological malignancies and solid tumors | |
| IL290011B1 (en) | Ezh2 inhibition in combination therapies for cancer treatment | |
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| HUE063299T2 (hu) | Daganatok kezelésére vagy megelõzésére szolgáló kombinációs terápia | |
| LT3481846T (lt) | 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles | |
| IL282904A (en) | Therapeutic microbiota for the treatment and/or prevention of dysbiosis | |
| SG11202002258WA (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness | |
| IL281997A (en) | Combined treatment for the treatment of uveal melanoma | |
| GB201807410D0 (en) | Diagnostic method and therapy | |
| GB201918404D0 (en) | Compounds and their use for the treatment of aplha1-antitrypsin deficiency | |
| PL3685167T3 (pl) | Sposób diagnozy i prognozy chorób neurodegeneracyjnych i neurozapalnych | |
| IL276905A (en) | Treatment and prevention of preeclampsia | |
| IL251135A (en) | A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment | |
| EP3650035B8 (fr) | Extrait d'algues rouges pour son utilisation pour la prevention ou le traitement d'un trouble intestinal | |
| SG11202006617RA (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| IL287050A (en) | Compounds for the treatment of oncovirus induced cancer and methods of use thereof | |
| HUE040273T2 (hu) | Termékek rozsdamentes acél preventív kezelésére és ezekkel kapcsolatos eljárások | |
| IL280262A (en) | Compositions and methods for treating cancer | |
| PT3191112T (pt) | Compostos de dipeptidilcetoamida e sua utilização para o tratamento e/ou prevenção da acumulação de gordura | |
| GB201617715D0 (en) | Methods for the treatment and prevention of ebola | |
| PT3687567T (pt) | Ligante anti-adrenomedulina (adm) para utilização em terapia ou prevenção de sintomas de doença | |
| HK40040059A (en) | Gremlin-1 antagonist for the prevention and treatment of cancer | |
| HK40061584A (en) | Therapeutic microbiota for the treatment and/or prevention of dysbiosis |